CRISPR Therapeutics and MaxCyte have extended their non-exclusive licensing agreement covering the use of MaxCyte’s flow electroporation technology into the field of oncology.
09 Nov 2018
Extension of clinical and commercial license with CRISPR Therapeutics
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Extension of clinical and commercial license with CRISPR Therapeutics
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
09 Nov 2018 -
Author:
Mick Cooper PhD -
Pages:
2
CRISPR Therapeutics and MaxCyte have extended their non-exclusive licensing agreement covering the use of MaxCyte’s flow electroporation technology into the field of oncology.